Share Price and Basic Stock Data
Last Updated: December 10, 2025, 11:12 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Centenial Surgical Suture Ltd operates in the medical equipment and accessories sector, a niche yet critical space, especially as healthcare demand continues to rise in India. The company recorded total sales of ₹52.66 Cr for FY 2023, which reflects a notable recovery from the previous year’s ₹44.43 Cr. However, the sales figures exhibit a rather flat trajectory in the recent quarters, hovering around ₹13 Cr, with a slight decline to ₹12.05 Cr in March 2024. This stagnation raises questions about growth strategies and market competitiveness. The company’s ability to innovate and adapt to changing healthcare needs will be pivotal for sustaining revenue growth. The operating profit margin (OPM) also saw a substantial improvement, reaching 15.48% by March 2025, which signals better cost management despite the revenue challenges. Overall, while the revenue trends show some resilience, they also highlight the need for a more aggressive growth strategy to capture market share in a competitive landscape.
Profitability and Efficiency Metrics
Profitability metrics for Centenial Surgical Suture Ltd reveal a mixed picture. The company reported a net profit of -₹1.94 Cr for FY 2025, a stark contrast to the net profit of ₹0.89 Cr in FY 2023. This decline raises concerns about profitability sustainability, particularly as the company grapples with rising expenses and interest costs. The interest coverage ratio (ICR) stood at a modest 1.70x, indicating that earnings are just enough to cover interest expenses, which could be a red flag for investors. Furthermore, the company’s return on equity (ROE) at 4.64% and return on capital employed (ROCE) at 3.94% are below industry expectations, suggesting that Centenial may not be effectively utilizing its capital to generate returns. On the efficiency front, the cash conversion cycle (CCC) of 895.19 days indicates prolonged inventory and receivables management, which could further strain cash flows if not addressed. Thus, while the improvement in OPM is commendable, overall profitability remains a significant challenge.
Balance Sheet Strength and Financial Ratios
The balance sheet of Centenial Surgical Suture Ltd presents a mixed bag of strengths and weaknesses. On one hand, the company maintains a healthy reserve of ₹25.27 Cr, which provides a buffer against financial volatility. However, the borrowings have climbed to ₹10.81 Cr, raising the debt-to-equity ratio to 0.39, a level that suggests moderate financial leverage. While this isn’t alarming, it does indicate that the company is relying more on debt financing, which can be risky in a fluctuating interest rate environment. The current ratio at 1.98x suggests that Centenial is comfortably positioned to meet its short-term obligations. However, with a price-to-book value ratio of 1.94x, the stock appears slightly overvalued compared to its book value, which may concern potential investors. Overall, while the balance sheet reflects a degree of stability, the increasing debt levels warrant cautious monitoring.
Shareholding Pattern and Investor Confidence
Centenial’s shareholding structure shows a significant presence of public investors, who hold 53.11% of the company, compared to promoters’ 46.89%. This indicates a relatively balanced ownership distribution, which can foster a sense of shared governance. However, the lack of foreign institutional and domestic institutional investors might suggest a hesitance from larger investors, potentially reflecting concerns over the company’s recent profitability issues. The number of shareholders has been gradually increasing, rising to 1,193 by March 2025 from 895 in March 2023. This uptick could indicate growing retail interest, but it may also be a sign of speculative trading rather than long-term confidence. As the company navigates its financial challenges, the dynamics of shareholder confidence will be crucial in determining its market performance and overall valuation in the coming periods.
Outlook, Risks, and Final Insight
Looking ahead, Centenial Surgical Suture Ltd faces a mixed outlook, influenced by both growth opportunities and inherent risks. The company operates in a sector with increasing demand, particularly as healthcare technologies advance. However, the persistent losses and declining net profit raise significant concerns. Risks such as rising interest costs, extended cash conversion cycles, and flat revenue growth may hinder its ability to attract institutional investors and sustain operational efficiency. Investors should also be wary of the company’s reliance on debt financing, which could become burdensome if market conditions worsen. Overall, while the company has potential in a growing industry, its current financial health reflects challenges that need urgent attention. Investors contemplating a position in Centenial should weigh these factors carefully, looking for signs of strategic improvements and operational efficiencies before making a commitment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Centenial Surgical Suture Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 79.5 Cr. | 63.5 | 129/46.0 | 18.1 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 35.0 Cr. | 95.9 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 24.5 Cr. | 17.0 | 26.5/14.0 | 11.8 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 19,113 Cr. | 1,886 | 2,980/1,821 | 52.8 | 288 | 0.19 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 73.1 Cr. | 40.1 | 86.9/40.0 | 21.9 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 19,113.00 Cr | 420.50 | 26.15 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.75 | 13.49 | 13.01 | 13.13 | 13.02 | 13.66 | 13.10 | 12.38 | 12.05 | 13.74 | 14.27 | 12.20 | 13.31 |
| Expenses | 10.61 | 12.38 | 11.98 | 12.06 | 11.92 | 12.50 | 11.96 | 11.19 | 10.54 | 12.02 | 12.54 | 11.45 | 11.25 |
| Operating Profit | 1.14 | 1.11 | 1.03 | 1.07 | 1.10 | 1.16 | 1.14 | 1.19 | 1.51 | 1.72 | 1.73 | 0.75 | 2.06 |
| OPM % | 9.70% | 8.23% | 7.92% | 8.15% | 8.45% | 8.49% | 8.70% | 9.61% | 12.53% | 12.52% | 12.12% | 6.15% | 15.48% |
| Other Income | 0.04 | 0.00 | 0.08 | 0.02 | 0.03 | 0.01 | 0.02 | 0.06 | 0.03 | 0.00 | 0.06 | 0.01 | 0.05 |
| Interest | 0.52 | 0.37 | 0.39 | 0.39 | 0.52 | 0.48 | 0.52 | 0.51 | 0.95 | 0.53 | 0.53 | 0.50 | 2.19 |
| Depreciation | 0.37 | 0.34 | 0.31 | 0.34 | 0.31 | 0.30 | 0.32 | 0.33 | 0.44 | 0.79 | 1.09 | 1.11 | 1.26 |
| Profit before tax | 0.29 | 0.40 | 0.41 | 0.36 | 0.30 | 0.39 | 0.32 | 0.41 | 0.15 | 0.40 | 0.17 | -0.85 | -1.34 |
| Tax % | 68.97% | 25.00% | 26.83% | 22.22% | 53.33% | 25.64% | 28.12% | 24.39% | -26.67% | 25.00% | 23.53% | 0.00% | -11.19% |
| Net Profit | 0.08 | 0.30 | 0.30 | 0.28 | 0.14 | 0.29 | 0.24 | 0.31 | 0.19 | 0.30 | 0.13 | -0.85 | -1.18 |
| EPS in Rs | 0.22 | 0.82 | 0.82 | 0.77 | 0.38 | 0.79 | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | -2.33 | -3.23 |
Last Updated: May 31, 2025, 6:34 am
Below is a detailed analysis of the quarterly data for Centenial Surgical Suture Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 13.31 Cr.. The value appears strong and on an upward trend. It has increased from 12.20 Cr. (Dec 2024) to 13.31 Cr., marking an increase of 1.11 Cr..
- For Expenses, as of Mar 2025, the value is 11.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.45 Cr. (Dec 2024) to 11.25 Cr., marking a decrease of 0.20 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.75 Cr. (Dec 2024) to 2.06 Cr., marking an increase of 1.31 Cr..
- For OPM %, as of Mar 2025, the value is 15.48%. The value appears strong and on an upward trend. It has increased from 6.15% (Dec 2024) to 15.48%, marking an increase of 9.33%.
- For Other Income, as of Mar 2025, the value is 0.05 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.05 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Mar 2025, the value is 2.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.50 Cr. (Dec 2024) to 2.19 Cr., marking an increase of 1.69 Cr..
- For Depreciation, as of Mar 2025, the value is 1.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.11 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Mar 2025, the value is -1.34 Cr.. The value appears to be declining and may need further review. It has decreased from -0.85 Cr. (Dec 2024) to -1.34 Cr., marking a decrease of 0.49 Cr..
- For Tax %, as of Mar 2025, the value is -11.19%. The value appears to be improving (decreasing) as expected. It has decreased from 0.00% (Dec 2024) to -11.19%, marking a decrease of 11.19%.
- For Net Profit, as of Mar 2025, the value is -1.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.85 Cr. (Dec 2024) to -1.18 Cr., marking a decrease of 0.33 Cr..
- For EPS in Rs, as of Mar 2025, the value is -3.23. The value appears to be declining and may need further review. It has decreased from -2.33 (Dec 2024) to -3.23, marking a decrease of 0.90.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.49 | 52.72 |
| Expenses | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.07 | 46.95 |
| Operating Profit | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.42 | 5.77 |
| OPM % | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 12.00% | 10.94% |
| Other Income | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | 0.12 |
| Interest | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.90 | 3.54 |
| Depreciation | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 4.25 | 4.41 |
| Profit before tax | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 | -2.06 |
| Tax % | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | -9.32% | |
| Net Profit | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | -1.94 |
| EPS in Rs | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | -4.00 | -5.31 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.26% | -18.75% | 10.26% | -10.47% | 31.17% | -35.64% | -26.15% | -34.38% | 41.27% | 26.97% | -229.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | -26.01% | 29.01% | -20.72% | 41.63% | -66.81% | 9.49% | -8.22% | 75.64% | -14.30% | -256.17% |
Centenial Surgical Suture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -287% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 29% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
| Reserves | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 25.33 | 25.27 |
| Borrowings | 11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | 30.01 | 10.81 |
| Other Liabilities | 19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | 23.83 | 41.78 |
| Total Liabilities | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
| Fixed Assets | 4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | 19.99 | 18.68 |
| CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 64.60 | 64.60 |
| Total Assets | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
Below is a detailed analysis of the balance sheet data for Centenial Surgical Suture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.42 Cr..
- For Reserves, as of Sep 2025, the value is 25.27 Cr.. The value appears to be declining and may need further review. It has decreased from 25.33 Cr. (Mar 2025) to 25.27 Cr., marking a decrease of 0.06 Cr..
- For Borrowings, as of Sep 2025, the value is 10.81 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 30.01 Cr. (Mar 2025) to 10.81 Cr., marking a decrease of 19.20 Cr..
- For Other Liabilities, as of Sep 2025, the value is 41.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.83 Cr. (Mar 2025) to 41.78 Cr., marking an increase of 17.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 83.28 Cr.. The value appears to be improving (decreasing). It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.68 Cr.. The value appears to be declining and may need further review. It has decreased from 19.99 Cr. (Mar 2025) to 18.68 Cr., marking a decrease of 1.31 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 64.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.60 Cr..
- For Total Assets, as of Sep 2025, the value is 83.28 Cr.. The value appears to be declining and may need further review. It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
Notably, the Reserves (25.27 Cr.) exceed the Borrowings (10.81 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.75 | -7.04 | -8.43 | -10.35 | -9.90 | -7.69 | -6.79 | -8.36 | -4.81 | -5.52 | -18.09 | -23.59 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.56 |
| Inventory Days | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 | 921.61 |
| Days Payable | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 | 151.98 |
| Cash Conversion Cycle | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 | 895.19 |
| Working Capital Days | 122.62 | 127.27 | 148.80 | 156.25 | 164.05 | 167.69 | 172.36 | 282.37 | 236.68 | 207.73 | 226.67 | 210.99 |
| ROCE % | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% | 3.94% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Diluted EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Cash EPS (Rs.) | 5.14 | 4.65 | 4.03 | 3.97 | 4.63 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Revenue From Operations / Share (Rs.) | 98.66 | 94.37 | 97.07 | 81.90 | 68.09 |
| PBDIT / Share (Rs.) | 11.77 | 9.46 | 8.16 | 8.28 | 9.40 |
| PBIT / Share (Rs.) | 3.92 | 6.90 | 5.76 | 5.47 | 6.54 |
| PBT / Share (Rs.) | -2.98 | 2.35 | 2.70 | 1.98 | 2.82 |
| Net Profit / Share (Rs.) | -2.70 | 2.09 | 1.63 | 1.16 | 1.77 |
| PBDIT Margin (%) | 11.92 | 10.02 | 8.40 | 10.11 | 13.80 |
| PBIT Margin (%) | 3.97 | 7.30 | 5.93 | 6.67 | 9.60 |
| PBT Margin (%) | -3.02 | 2.48 | 2.77 | 2.41 | 4.14 |
| Net Profit Margin (%) | -2.73 | 2.21 | 1.68 | 1.41 | 2.60 |
| Return on Networth / Equity (%) | -4.75 | 3.52 | 2.85 | 2.07 | 3.25 |
| Return on Capital Employeed (%) | 4.03 | 8.08 | 8.37 | 8.00 | 9.20 |
| Return On Assets (%) | -1.73 | 1.43 | 1.33 | 1.02 | 1.37 |
| Total Debt / Equity (X) | 0.39 | 0.44 | 0.31 | 0.30 | 0.41 |
| Asset Turnover Ratio (%) | 0.65 | 0.70 | 0.82 | 0.67 | 0.53 |
| Current Ratio (X) | 1.98 | 1.99 | 2.04 | 2.20 | 1.92 |
| Quick Ratio (X) | 0.61 | 0.69 | 0.76 | 0.86 | 0.77 |
| Inventory Turnover Ratio (X) | 1.24 | 0.50 | 0.58 | 0.45 | 0.46 |
| Interest Coverage Ratio (X) | 1.70 | 2.08 | 2.66 | 2.37 | 2.53 |
| Interest Coverage Ratio (Post Tax) (X) | 0.60 | 1.46 | 1.53 | 1.33 | 1.48 |
| Enterprise Value (Cr.) | 71.71 | 63.31 | 43.04 | 41.99 | 34.92 |
| EV / Net Operating Revenue (X) | 1.34 | 1.24 | 0.81 | 0.94 | 0.94 |
| EV / EBITDA (X) | 11.23 | 12.34 | 9.72 | 9.35 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| Price / BV (X) | 1.94 | 1.54 | 1.08 | 1.09 | 0.78 |
| Price / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| EarningsYield | -0.02 | 0.02 | 0.02 | 0.01 | 0.04 |
After reviewing the key financial ratios for Centenial Surgical Suture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.14. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 5.14, marking an increase of 0.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 98.66. It has increased from 94.37 (Mar 24) to 98.66, marking an increase of 4.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.77. This value is within the healthy range. It has increased from 9.46 (Mar 24) to 11.77, marking an increase of 2.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.92. This value is within the healthy range. It has decreased from 6.90 (Mar 24) to 3.92, marking a decrease of 2.98.
- For PBT / Share (Rs.), as of Mar 25, the value is -2.98. This value is below the healthy minimum of 0. It has decreased from 2.35 (Mar 24) to -2.98, marking a decrease of 5.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 2. It has decreased from 2.09 (Mar 24) to -2.70, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 10.02 (Mar 24) to 11.92, marking an increase of 1.90.
- For PBIT Margin (%), as of Mar 25, the value is 3.97. This value is below the healthy minimum of 10. It has decreased from 7.30 (Mar 24) to 3.97, marking a decrease of 3.33.
- For PBT Margin (%), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 10. It has decreased from 2.48 (Mar 24) to -3.02, marking a decrease of 5.50.
- For Net Profit Margin (%), as of Mar 25, the value is -2.73. This value is below the healthy minimum of 5. It has decreased from 2.21 (Mar 24) to -2.73, marking a decrease of 4.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is -4.75. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to -4.75, marking a decrease of 8.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 8.08 (Mar 24) to 4.03, marking a decrease of 4.05.
- For Return On Assets (%), as of Mar 25, the value is -1.73. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to -1.73, marking a decrease of 3.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.39, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.70 (Mar 24) to 0.65, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.98, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.69 (Mar 24) to 0.61, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 4. It has increased from 0.50 (Mar 24) to 1.24, marking an increase of 0.74.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.70. This value is below the healthy minimum of 3. It has decreased from 2.08 (Mar 24) to 1.70, marking a decrease of 0.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 3. It has decreased from 1.46 (Mar 24) to 0.60, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 71.71. It has increased from 63.31 (Mar 24) to 71.71, marking an increase of 8.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.34, marking an increase of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 11.23. This value is within the healthy range. It has decreased from 12.34 (Mar 24) to 11.23, marking a decrease of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For Price / BV (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.94, marking an increase of 0.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.02, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Centenial Surgical Suture Ltd:
- Net Profit Margin: -2.73%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -4.75% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.61
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 26.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.73%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | F-29, MIDC, Murbad Thane Maharashtra 421401 | admin@centenialindia.com http://www.centenialindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Majrekar | Managing Director & CEO |
| Ms. Anuradha Kashikar | Executive Director & CFO |
| Mr. Devraj T Poojary | Executive Director |
| Mr. Neel M Vora | Ind. Non-Executive Director |
| Mr. Ridhima B Limaye | Ind. Non-Executive Director |
| Mr. Akash S Modi | Ind. Non-Executive Director |
| Mr. Anuj V Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Centenial Surgical Suture Ltd?
Centenial Surgical Suture Ltd's intrinsic value (as of 11 December 2025) is 47.76 which is 50.20% lower the current market price of 95.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 35.0 Cr. market cap, FY2025-2026 high/low of 189/82.2, reserves of ₹25.27 Cr, and liabilities of 83.28 Cr.
What is the Market Cap of Centenial Surgical Suture Ltd?
The Market Cap of Centenial Surgical Suture Ltd is 35.0 Cr..
What is the current Stock Price of Centenial Surgical Suture Ltd as on 11 December 2025?
The current stock price of Centenial Surgical Suture Ltd as on 11 December 2025 is 95.9.
What is the High / Low of Centenial Surgical Suture Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Centenial Surgical Suture Ltd stocks is 189/82.2.
What is the Stock P/E of Centenial Surgical Suture Ltd?
The Stock P/E of Centenial Surgical Suture Ltd is .
What is the Book Value of Centenial Surgical Suture Ltd?
The Book Value of Centenial Surgical Suture Ltd is 84.1.
What is the Dividend Yield of Centenial Surgical Suture Ltd?
The Dividend Yield of Centenial Surgical Suture Ltd is 0.00 %.
What is the ROCE of Centenial Surgical Suture Ltd?
The ROCE of Centenial Surgical Suture Ltd is 3.94 %.
What is the ROE of Centenial Surgical Suture Ltd?
The ROE of Centenial Surgical Suture Ltd is 4.64 %.
What is the Face Value of Centenial Surgical Suture Ltd?
The Face Value of Centenial Surgical Suture Ltd is 10.0.